ReWalk Robotics Ltd.: management transactions · United States · SEC (Form 4)

About ReWalk Robotics Ltd.

ReWalk Robotics Ltd. is a U.S.-listed medical technology company trading on Nasdaq under the ticker RWLK. Although the business has recently operated under the Lifeward brand and disclosed a planned 2026 name change to Morpheus, it remains known in the market for its robotic mobility and rehabilitation platforms. The company was founded in 2001 and is organized under Israeli law, with principal operations in Yokneam Illit, Israel, and a meaningful U.S. presence, including operations in Massachusetts. For investors, this is best understood as a medtech company rather than a traditional industrial robotics business. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1607962/000117891326001208/zk2634619.htm?utm_source=openai)) Its core business has historically centered on wearable robotic exoskeletons for people with spinal cord injury and other mobility impairments. The initial product set included the ReWalk Personal and ReWalk Rehabilitation systems, and the company has since expanded into a broader rehabilitation portfolio. Today, the main product lines include ReWalk, a personal exoskeleton designed for everyday mobility; ReStore, a soft robotic system used in stroke rehabilitation; and AlterG products and services, which extend the company’s reach into physical therapy and recovery solutions. This portfolio gives the company exposure to several adjacent markets within rehabilitation technology, while preserving its identity as a leader in powered mobility assistance. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1607962/000117891322000800/zk2227327.htm?utm_source=openai)) From a competitive standpoint, ReWalk is one of the early pioneers in personal exoskeletons and still benefits from strong brand recognition in a niche category. However, the addressable market remains relatively narrow and highly dependent on regulatory approval, reimbursement, and clinician adoption. A major milestone came in March 2025, when the FDA cleared ReWalk 7, followed by a U.S. commercial launch in April 2025. In 2024, Medicare finalized a reimbursement pathway for personal exoskeletons, and the company later reported progress with private payer coverage, including major U.S. insurers. These developments are important because reimbursement is often the gating factor for commercialization in medtech. ([ir.rewalk.com](https://ir.rewalk.com/news-releases/news-release-details/fda-issues-clearance-rewalk-7-exoskeleton?utm_source=openai)) Geographically, the company is international but remains heavily tied to the United States for commercialization, payer access, and capital markets visibility. Recent disclosures also indicate activity in Germany and other international markets through reimbursement agreements and distribution channels. Financially, recent company updates point to improving sales for ReWalk Personal and a strategic emphasis on proprietary products, while some non-core product revenues have declined. For English-speaking investors, RWLK/Nasdaq should be viewed as a small-cap, high-risk, high-optional medtech name: the upside case depends on adoption, reimbursement expansion, and execution, while the downside reflects its limited scale and ongoing regulatory-commercial dependency. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1607962/000117891325003854/zk2533971.htm?utm_source=openai))